Adaptive Biotechnologies (NASDAQ: ADPT) insider plans more sales after $7.96M already sold

Rhea-AI Filing Summary

Adaptive Biotechnologies Corp (ADPT) insider Chad Robins has filed a notice of proposed sale of common stock under Rule 144. He plans to sell 278,676 shares through Goldman Sachs & Co. LLC via a cashless exercise/same-day sale of stock options originally granted on February 7, 2018. The planned sale represents part of an issuer share base of 159,595,842 shares outstanding. Over the prior three months, Robins has already sold 321,324 shares of common stock.

Key Figures

Shares to be sold: 278,676 shares Aggregate market value of proposed sale: $6,844,282.56 Shares outstanding: 159,595,842 shares +3 more

6 metrics

Shares to be sold 278,676 shares Proposed sale of ADPT common stock under Rule 144

Aggregate market value of proposed sale $6,844,282.56 Value of 278,676 shares to be sold

Shares outstanding 159,595,842 shares Issuer’s common stock referenced in the notice

Shares sold in past 3 months 321,324 shares Chad Robins’ prior ADPT common stock sales

Value of shares sold in past 3 months $7,959,195.48 Aggregate proceeds from prior 3-month sales

Option grant date 02/07/2018 Date stock options underlying the sale were acquired as compensation

Key Terms

Rule 144, cashless exercise, same-day sale, aggregate market value

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

cashless exercise financial

"Compensation -- Cashless exercise / same-day sale"

A cashless exercise is a way for an option holder to convert stock options into actual shares without paying the purchase price in cash; instead they immediately give up a portion of the newly issued shares to cover the cost and any withholding taxes. Investors care because this process increases the number of shares available and can slightly dilute existing holdings, while also signaling how insiders or employees are realizing compensation without needing cash — similar to paying for a purchase by handing over part of what you just bought.

same-day sale financial

"Compensation -- Cashless exercise / same-day sale"

aggregate market value financial

"278676 | 6844282.56 | 159595842"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

FAQ

What did ADPT insider Chad Robins file in this Form 144?

Chad Robins filed a Rule 144 notice for a proposed sale of 278,676 shares of Adaptive Biotechnologies common stock through Goldman Sachs & Co. LLC via a cashless exercise and same-day sale.

How many ADPT shares does Chad Robins plan to sell and what is the value?

Chad Robins plans to sell 278,676 shares of ADPT common stock with an indicated aggregate market value of $6,844,282.56, according to the Rule 144 notice filed through his broker.

What are Adaptive Biotechnologies’ shares outstanding referenced in this Form 144?

The notice references 159,595,842 shares outstanding of Adaptive Biotechnologies common stock, providing context for the relative size of Chad Robins’ proposed Rule 144 sale.

What ADPT stock sales has Chad Robins made in the last three months?

Over the past three months, Chad Robins has sold 321,324 shares of Adaptive Biotechnologies common stock for an aggregate amount of $7,959,195.48, as disclosed in the Rule 144 filing.

How were the ADPT shares to be sold by Chad Robins originally acquired?

The shares underlying the proposed sale were acquired as compensation via stock options granted on February 7, 2018, and are expected to be disposed of through a cashless exercise/same-day sale structure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/18/2026 - 05:46 PM Accepted by SEC EDGAR 08/18/2026 - 05:45 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001780649
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Adaptive Biotechnologies Corporation
SEC File Number	001-38957
Address of Issuer	1165 Eastlake Avenue East Seattle WASHINGTON 98109
Phone	1-206-659-0067
Name of Person for Whose Account the Securities are To Be Sold	Chad Robins
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Goldman Sachs & Co. LLC 200 West Street New York NY 10282	278676	6844282.56	159595842	08/18/2026	NASD

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	02/07/2018	Acquired as compensation -- Stock Options	The Issuer			278676	02/07/2018	Compensation -- Cashless exercise / same-day sale

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Chad M. Robins 1165 Eastlake Avenue East Seattle WA 98109	Common Stock	08/17/2026	321324	7959195.48

144: Remarks and Signature

Remarks
Date of Notice	08/18/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Goldman Sachs & Co. LLC on behalf of Chad Robins
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)